Antidepressant application of composition of paeoniflorin and albiflorin and preparation method thereof

A technology of paeonifloride glycosides and paeoniflorin, applied in the preparation of paeonifloride glycosides composition and extracts, paeoniflorin, nutrition and health food, and pharmaceutical fields, which can solve problems such as side effects and calm down patients

CN101940583AInactive Publication Date: 2011-01-12张作光
3 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2011-01-12
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a pharmaceutical composition for the treatment of depression prepared by raw materials of paeoniflorin and albiflorin. The invention also discloses a preparation method of the pharmaceutical composition. The experiments prove that the pharmaceutical composition of the invention can obviously reduce the suspension tail immovability time of the mouse to be tested, from which the antidepressant function of the composition in the experiment can be inferred; the pharmaceutical composition of the invention can obviously withstand the temperature reduction of the mouse caused by the reserpine, from which the relevance of the antidepressan mechanism of the composition and the regulation of the monoamine transmitters can be inferred; and the pharmaceutical composition of the invention can significantly reduce the amounts of horizontal movement and vertical movement of the model rat, reduce the electric shock times in the training period and testing period of step down passive avoidance test, significantly reduce the CRH secretion of hypothalamus and ACTH secretion of hypophysis, and significantly reduce the CORT content in the blood, from which the antidepressant function of the pharmaceutical composition and one of the mechanisms of excessive hyperfunction suppression of HPA axis can be inferred.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a group of pharmaceutical compositions and extracts made from paeoniflorin and paeonifloride diglycosides for treating depression, which can be used as medicine, nutritional agent and health food.

[0002] The present invention also relates to the preparation method of the above-mentioned paeoniflorin and paeonifloride diglycoside composition and extract for treating depression. Background technique

[0003] Depression is a common illness. According to statistics, about 25% of women in the general population have experienced depression in their lifetime, and about 10% of men have experienced depression (Zhang Chunxing: "Modern Psychology"). Information provided by the World Health Organization: The incidence of depression in the world is about 11%. There are currently about 340 million mentally depressed patients in the world, and this number is still on the rise. The survey found that depression will increase in the next 20 y...

Examples

Embodiment 1

[0029] See attached figure 2 150 kilograms of Radix Paeoniae Alba (conforming to the provisions of the Pharmacopoeia of the People's Republic of China) are broken, heated and refluxed 3 times with 70% ethanol aqueous solution, and the solvent weights for the 3 times are respectively 5 times, 4 times, and 3 times that of Radix Paeoniae Alba, concentrated Recover ethanol, dilute the paste to 4 times the volume, filter the clarified liquid onto the ME-1 macroporous resin adsorption column, adsorb at a flow rate of 1 bed volume / hour, first wash with 4 times the bed volume of water, and then use 2 times the bed volume Volume of 10% ethanol rinses, then analyzes with 20% ethanol, collects the analysis solution of the 2nd, 3, 4, and 5 bed volumes, concentrates and dries, and obtains 4.5 kilograms of Radix Paeoniae Alba extract (containing 48.89% paeoniflorin, 18.99% % paeonylide), which is the pharmaceutical composition of the present invention.

Embodiment 2

[0031] See attached figure 1 3g of paeoniflorin with a purity of 90% and 1.2g of paeonifloride with a purity of 90% are directly mixed and pulverized, and 0.1g of starch, 0.1g of lactose, and 0.1g of micropowdered silica gel are added to obtain the pharmaceutical composition preparation of the present invention.

experiment example 1 Embodiment 1

[0032] Experimental Example 1 Effect of Example 1 on Mouse Tail Suspension Time

[0033] 1. Experimental materials

[0034] 1.1 ICR mice, male, weighing 18-22g. Provided by Weitong Lihua Animal Experiment Center, certificate number: 2007-0001.

[0035] 1.2 Experimental drugs: Example 1, Beijing Onal Bioengineering Technology Co., Ltd., batch number: 0803. Positive drug: fluoxetine hydrochloride (Fluooxetine, Prozac), Eli Lilly Suzhou Pharmaceutical Co., Ltd., batch number: J20030017, the dosage for mice is 3.5 mg / kg. Preparation method: Take out the contents of the capsule and prepare a solution with deionized water.

[0036] 1.3 Experimental equipment: Medlab biological signal acquisition system (Nanjing Yimei Technology Co., Ltd.), JZ100 100g tension transducer (Gaobeidian Xinhang Electromechanical Equipment Co., Ltd.).

[0037] 2. Experimental method

[0038] 2.1 Grouping and administration

[0039] Normal mice were randomly divided into 5 groups, namely blank control...